Proven CRYOcheck™ Chromogenic Factor VIII assay now offers expanded utility in anticipation of emerging treatments HALIFAX, NS, Sept. 10, 2025 /PRNewswire/ -- Precision BioLogic Inc., a leading ...

Precision BioLogic originally developed CRYOcheck Chromogenic Factor VIII in response to a growing demand for chromogenic assays 1. Launched in 2020, it was the first commercially available, ...

HALIFAX, NS, Sept. 10, 2025 /CNW/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the expanded utility of its CRYOcheck Chromogenic Factor VIII ...

NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat ® KMT2A + MRD Assay and Software ...

Next-generation sequencing (NGS) has become increasingly popular with testing labs, as it allows them to obtain more data in less time and with minimal input. In this webinar, we will explore the Ion ...

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, announced the addition of the LeukoStrat KMT2A + MRD Assay and Software to its industry-leading oncology ...